EP Solutions Secures $4 Million in Series A Funding for ground-breaking Amycard 01C Electrophysiology Workstation technology

EP Solutions SA, a pioneering Swiss company founded in 2019 and based in Yverdon, has successfully raised an impressive $4 million in its latest funding round. This financial boost aims to further the development, industrialization, and marketing of the cutting-edge Amycard 01C electrophysiology workstation. Designed with the intent to revolutionize cardiac diagnostics and treatment, the Amycard 01C utilizes advanced software to record ECG data and construct detailed 3D heart models. This innovative workstation provides an unparalleled view into the heart's electrical activity, enabling real-time recordings of the four chambers and generating comprehensive cardiac excitation maps of both the epi- and endocardium. With a strong focus on efficiency and patient safety, EP Solutions' technology not only reduces patient risk but also optimizes therapy outcomes, leading to enhanced diagnostic accuracy, decreased X-ray exposure, and shortened surgery times in the cath lab. Additionally, the improved approach facilitates significant savings on catheter use—a notable concern in cardiac procedures. This funding will power EP Solutions' commitment to transforming electrophysiology by advancing its product line and enhancing its marketing efforts, positioning the company as a leader in cardiac care technology. With the Amycard 01C, EP Solutions is set to redefine how clinicians approach heart disease diagnosis and treatment, ultimately benefiting patients around the globe.